Titre : | Use of buprenorphine in pregnancy: patient management and effects on the neonate (2003) |
Titre traduit : | (Buprénorphine pendant la grossesse : prise en charge du patient et effets chez le nouveau-né) |
Auteurs : | R. E. JOHNSON ; H. E. JONES ; G. FISCHER |
Type de document : | Article : Périodique |
Dans : | Drug and Alcohol Dependence (Vol.70, n°2 Suppl., May 2003) |
Article en page(s) : | S87-S101 |
Note générale : |
Drug and Alcohol Dependence, 2003, 70, (2, Suppl. 1), S87-S101 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés BUPRENORPHINE ; OPIACES ; DEPENDANCE ; GROSSESSE ; NOUVEAU-NE ; SYNDROME DE SEVRAGE ; MERE ; PRISE EN CHARGE |
Résumé : |
ENGLISH : It is estimated that 55-94% of infants born to opioid-dependent mothers in US will show signs of opioid withdrawal. Buprenorphine has been reported to produce little or no autonomic signs or symptoms of opioid withdrawal following abrupt termination in adults. To date, there have been 21 published reports representing approximately 15 evaluable cohorts of infants exposed to buprenorphine in utero. Of approximately 309 infants exposed, a neonatal abstinence syndrome (NAS) has been reported in 62% infants with 48% requiring treatment; apparently greater than 40% of these cases are confounded by illicit drug use. The NAS associated with buprenorphine generally appears within 12-48 h, peaks at approximately 72-96 h, and lasts for 120-168 h. These results appear similar to or less than that observed following in utero exposure to methadone. From a review of the literature, buprenorphine appears to be safe and effective in both mother and infant with an NAS that may differ from methadone both qualitatively and quantitatively. (Review's abstract.) |
Note de contenu : | tabl. |
Domaine : | Drogues illicites / Illicit drugs |
Sous-type de document : | Revue de la littérature / Literature review |
Refs biblio. : | 95 |
Affiliation : |
Clinc., Sci. Regul. Aff., Reckitt Benckiser Pharmaceutic. Etats-Unis. United States. |
Numéro Toxibase : | 804407 |
Centre Emetteur : | 08 CAS Strasbourg |
Accueil